Regeneron Pharmaceuticals Inc
CRISPR Stocks Are Soaring Amid Biotech Breakthrough
Analysts’ Recommendations for United Therapeutics
In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.
Analysts’ Recommendations for Regeneron and Peers in June 2017
On March 28, 2017, Regeneron and Sanofi’s Dupixent secured FDA approval as an injectable treatment for patients suffering from moderate-to-severe eczema.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
Analysts’ Recommendations for Mylan in September 2017
In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.
Restricted Access Continues to Impact Praluent Sales in 2016
Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.
Taking Stock of Regeneron Pharmaceuticals’ Marketed Products
Globally, Regeneron Pharmaceuticals’ (REGN) Eyelea generated $5.9 billion in sales in fiscal 2017 compared with $5.1 billion in fiscal 2016.
Regeneron Continues to Trade at Premium
Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.
What Analysts Recommend for Celgene in 2017
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?
Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.
Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor
the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.
Amgen Continues to Be Confident in Repatha in 2017
In 1Q17, Amgen’s (AMGN) PCSK9 inhibitor therapy, Repatha, reported revenue of nearly $49 million. The drug earned $33 million in revenue in US markets and $16 million in international revenue.
XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study
The large-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 0.3% on April 20, 2016. Large-cap stocks account for 19.3% of XBI’s portfolio.
SPDR S&P Biotech ETF (XBI) Had a Mixed Day on October 8
The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Teva Stock Continues to Trend Higher on Positive News
Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.
Why Eylea Could Face Tough Competition in 2016
In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.
Ionis Pharmaceuticals’ Valuation on May 23
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.
Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?
In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.
BioMarin to Cross $1 Billion Revenue in 2016
BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.
BioMarin: Why So Many ‘Buy’ Recommendations?
BioMarin (BMRN) is expected to report 2Q16 earnings on August 4, 2016. “Buy” ratings have increased to 94.7% from 90% on June 29, 2016.
Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?
Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.
What Do Analysts Recommend for United Therapeutics?
23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”
How Regeneron Is Working to Maintain Eylea’s Dominance
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.
Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials
Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.
FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.
Viking Global buys a new stake in Regeneron Pharmaceuticals
Viking Global Investors revealed a brand new position valued at around $315 million in Regeneron Pharmaceuticals (REGN) last quarter. The position accounts for 1.32% of Viking’s total portfolio.
The IBB Biotechnology ETF: The Drugs You Need?
The iShares NASDAQ Biotechnology ETF (IBB) aims to track the investment results of the NASDAQ Biotechnology Index, which comprises NASDAQ-listed biotechnology and pharmaceuticals companies.
Understanding Regeneron’s Share Price Movement after Its 4Q15 Results
Regeneron Pharmaceuticals (REGN) earned $1.1 billion in 4Q15, which translates to a 37% YoY (year-over-year) sales growth.
Factors That Will Determine Repatha’s Future Commercial Success
Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.
Regeneron’s Dupixent Approved for Atopic Dermatitis
In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.
What Drove Regeneron’s 3Q16 Performance?
In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.
BioMarin Leads in the Market for Mucopolysaccharidoses Disorders
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.
Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.
Dupixent May Be Strong Growth Driver for Sanofi in the Future
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug
On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.
Eylea Could Continue to Generate High Revenue
Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.
Repatha Represents a Solid Growth Opportunity for Amgen in 2017
Despite Amgen’s efforts to improve access for Repatha, the drug has seen high rejection rates in the US due to stringent preauthorization requirements.
Why did Halvorsen’s Viking Global boost its position in Illumina?
Viking Global Investors significantly increased its position in Illumina (ILMN) last quarter. The position, which accounted for 0.88% of Viking’s total 4Q 2013 portfolio, is now the fund’s third largest position, at 5.53% of the 1Q 2014 portfolio.
Why Biogen’s Stock Price Has Fallen
Biogen (BIIB) was the worst-performing stock within the Health Care Select Sector SPDR ETF (XLV) on June 7, 2016.
Amgen’s Repatha and Blincyto: How They Did in 3Q17
In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.
Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up
Regeneron to Partner With Roche on COVID-19 Drug
Gilead Sciences on the Street in January: Analyst Recommendations
In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.
Why Are Most Analysts Recommending a ‘Buy’ for Vertex?
On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.
How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release
Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.
Why Is Vertex Pharmaceuticals’ Valuation at a Discount?
On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).
How Did Exelixis Perform in 1Q18?
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
XLV Gains May 10, Trades above Its 20-Day Moving Average
On May 10, 2016, the top gainers of XLV were Allergan (AGN) and Regeneron Pharmaceuticals (REGN). They rose by 5.3% and 2.8%, respectively.
Incyte Was a Star Performer from August 10–17, 2015
By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.
What Can Investors Expect from Regeneron’s 4Q15 Earnings?
Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.
Amgen has attractive, high-growth assets
The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.
What Amgen’s Analysts Recommend in August 2017
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”
Regeneron Is Down despite Earnings Beat
Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.
Sanofi’s Immunology Portfolio in the First Quarter
In the first quarter, Sanofi’s (SNY) Immunology Franchise reported net sales of 359 million euros.
Analyzing Sanofi’s Oncology Portfolio in the First Quarter
In the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange rate) basis.
Analysts Raise Their Target Price for Regeneron in March
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.
What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Do Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”
Regeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.
Austedo Is on Solid Growth Trajectory in 2018
In the third quarter, Austedo reported revenues of $62 million, which is a YoY rise of 933.33% and a sequential rise of 40.91%.
Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Regeneron and Alnylam Collaborate for NASH Research Program
Alnylam Pharmaceuticals (ALNY) is currently trading 1.47% higher than its 52-week low price of $78.85 and 48.04% lower than its 52-week high price of $153.99.
How Regeneron Stock Performed in the First Half of October
On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12.
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.
Analyzing Regenxbio’s Valuation Metrics
Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.
Why Vertex Is Expected to Report Robust EPS Growth in 2018
Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.
OPKO Health Expects Its Loss per Share to Shrink This Year
In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.
OPKO Health’s Q3 2018 Revenue Expectations
In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
Why Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.
Pediatric Atopic Dermatitis Indication May Boost Dupixent Revenue
A label expansion could further advance Dupixent’s position in the atopic dermatitis market.
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.
Solid Biosciences’ Stock Price Rose 46.6% on June 19
On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.
Regeneron Is Expected to Witness a Modest Revenue Rise in 2018
Regeneron (REGN) currently has six FDA-approved drugs and 17 investigational therapies in its research pipeline.
The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It
Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.
Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21.
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?
In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17.
How Regeneron’s Praluent and Dupixent Performed in 1Q18
In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.
Upadacitinib Could Drive AbbVie’s Long-Term Growth
In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis.
Exploring the Growth of Regeneron’s Praluent
In April 2017, the FDA approved a supplemental biologics license application (or sBLA) for Praluent for a once-monthly dose.
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.
Regeneron Pharmaceuticals’ Dupixent, Kevzara, and Zaltrap
In 4Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $139.0 million compared to $88.9 million in 3Q17.